Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch + Lomb Corporation filings document the reporting obligations of a Canada-incorporated eye health company whose common shares trade on the New York Stock Exchange and Toronto Stock Exchange under BLCO. Its 8-K reports cover quarterly and annual operating results, non-GAAP financial measures, guidance, investor presentations, material credit-agreement amendments and refinancing activity.
Proxy materials describe annual shareholder meeting matters, board composition, director independence, committee assignments and executive compensation governance. Other event filings record board appointments, committee changes, registered common-share details and Regulation FD disclosures tied to the company's product pipeline, Pharmaceuticals, Surgical and Vision Care operations.
Bausch & Lomb Corp Chairman and CEO Brent L. Saunders reported a routine tax-related share disposition. On May 22, 2026, 2,886 common shares at $15.92 per share were withheld to satisfy tax withholding obligations upon vesting of restricted share units. After this non-market transaction, Saunders directly holds 978,389 common shares, so the withheld amount represents only a small portion of his overall position.
Bausch + Lomb Corporation reported the results of its Annual Meeting of Shareholders held on May 20, 2026. Shareholders elected ten directors, including Eduardo Alfonso and Brenton L. Saunders, with each nominee receiving over 331 million votes in favor and around 4.2 to 4.3 million votes against, plus 11.45 million broker non-votes.
Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 328,089,056 votes for, 832,221 against, 6,896,414 abstentions and 11,452,072 broker non-votes. In addition, shareholders appointed PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm until the close of the 2027 annual meeting, with 343,283,263 votes for and 3,986,500 votes withheld.
Bausch & Lomb Corp EVP and CFO Sam Eldessouky reported a tax-related share disposition. On May 5, 2026, 63,938 common shares were withheld at $16.00 per share to satisfy tax withholding obligations upon vesting of restricted share units. This was not an open-market sale. After this withholding, Eldessouky directly holds 343,192 common shares of Bausch & Lomb Corp.
Bausch & Lomb Corp executive Yehia Hashad, EVP of R&D and CMO, reported a routine tax-related share disposition on Form 4. On May 5, 2026, 13,664 common shares at $16.00 per share were withheld to cover tax obligations triggered by the vesting of restricted share units, rather than sold in the open market. After this withholding, Hashad directly holds 166,377 common shares, indicating he retains a substantial equity stake in the company.
Bausch & Lomb Corp senior vice president, controller and chief accounting officer Frederick Munsch reported a routine share disposition related to taxes. On May 5, 2026, 8,673 Common Shares at $16.00 per share were withheld to cover tax obligations upon vesting of restricted share units, rather than sold on the open market.
After this tax-withholding event, Munsch directly holds 89,640 Common Shares. The filing reflects a compensation-related withholding, not an open-market purchase or sale decision.
Bausch & Lomb Corp executive Luc Bonnefoy, President of Surgical, reported a routine tax-related share disposition. On the vesting of restricted share units, 11,970 common shares were withheld by the company to satisfy tax withholding obligations, rather than sold on the open market. Following this withholding, Bonnefoy directly holds 88,031 common shares, showing he retains a substantial equity position after the RSU vesting event.
ROBERTSON RUSSEL C reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Russel C. Robertson received an equity award of 1,611 common shares on April 30, 2026. The filing describes these as restricted share units, each representing a contingent right to receive one common share of Bausch & Lomb.
After this grant, Robertson directly holds 78,418 common shares. This is a compensation-related grant, not an open-market purchase, and reflects additional alignment of the director’s interests with common shareholders through stock-based awards.
Bausch & Lomb Corp director John Paulson received an equity grant. He acquired 1,375 restricted share units, each representing a contingent right to receive one common share of Bausch & Lomb, at a reference price of $15.90 per share.
Following this grant, Paulson directly holds 73,981 common shares. This is a compensation-related award reported as an acquisition, not an open-market purchase or sale.
Bausch & Lomb Corp director Steven H. Collis received a grant of restricted share units in the company. On this award date, he acquired 1,415 restricted share units, each representing a contingent right to receive one common share of Bausch & Lomb. Following this award, his directly held common share-equivalent position reported in this filing is 26,161 shares.
Bausch & Lomb Corp director Alfonso Eduardo reported an acquisition of 1,375 common shares on April 30, 2026 through a grant of restricted share units. Each unit represents a contingent right to receive one common share at a reference price of $15.90 per share.
After this compensation-related award, Eduardo directly holds 15,230 common shares. This filing reflects an equity grant rather than an open-market purchase or sale, and does not involve any derivative exercises.